Meeting News CoverageVideo

VIDEO: Long-term Dupixent plus topical corticosteroid treatment effective for AD

ORLANDO, Fla. —In a video perspective from the American Academy of Dermatology Annual Meeting, Andrew Blauvelt, MD, MBA, discusses his late-breaking research presentation on Dupixent with concomitant topical corticosteroids to treat moderate-to-severe atopic dermatitis.

Blauvelt, president of Oregon Medical Research Center, Portland, found that long-term treatment with Dupixent (dupilumab, Regeneron and Sanofi) plus topical corticosteroids improved atopic dermatitis signs and symptoms, including pruritus, with acceptable safety for up to 1 year when compared with topical corticosteroid treatment alone.

ORLANDO, Fla. —In a video perspective from the American Academy of Dermatology Annual Meeting, Andrew Blauvelt, MD, MBA, discusses his late-breaking research presentation on Dupixent with concomitant topical corticosteroids to treat moderate-to-severe atopic dermatitis.

Blauvelt, president of Oregon Medical Research Center, Portland, found that long-term treatment with Dupixent (dupilumab, Regeneron and Sanofi) plus topical corticosteroids improved atopic dermatitis signs and symptoms, including pruritus, with acceptable safety for up to 1 year when compared with topical corticosteroid treatment alone.

    See more from American Academy of Dermatology Meeting